Related Experiment Video
Updated: Jun 18, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Prevention of type 1 diabetes
Diane K Wherrett1, Denis Daneman
1Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Ontario, Canada.
Abstract:
Prevention of loss of beta cells in type 1 diabetes is a major goal of current research. Knowledge of the genetic susceptibility, increasing ability to predict who may be at risk, recognition of the potential clinical impact of residual insulin secretion after diagnosis, and development of new immunomodulatory agents have supported an increasing number of clinical trials to prevent beta-cell loss. Interventions can be targeted at 3 stages: before the development of autoimmunity (primary prevention), after autoimmunity is recognized (secondary prevention), or after diagnosis when significant numbers of beta cells remain (tertiary prevention). Thus far, several agents show promise when given shortly after diagnosis, but no interventions before diagnosis have shown benefit. Knowledge in this area has grown quickly in recent years and will continue to grow rapidly with several international collaborative efforts underway.
Insights
Preventing beta-cell loss in type 1 diabetes is crucial. Current research focuses on immunomodulatory agents and clinical trials, with some agents showing promise shortly after diagnosis but no pre-diagnosis benefits yet.
Area of Science:
- Immunology
- Endocrinology
- Diabetes Research
Background:
- Type 1 diabetes involves autoimmune destruction of insulin-producing beta cells.
- Identifying individuals at risk and preserving residual beta-cell function are key research objectives.
- Advances in understanding genetic susceptibility and immunomodulation are driving new therapeutic strategies.
Purpose of the Study:
- To review current strategies and clinical trial progress in preventing beta-cell loss in type 1 diabetes.
- To categorize interventions based on the stage of disease: primary, secondary, and tertiary prevention.
- To assess the efficacy of existing and emerging treatments for beta-cell preservation.
Main Methods:
- Review of recent scientific literature and ongoing clinical trials.
- Analysis of intervention strategies targeting different stages of type 1 diabetes development.
- Evaluation of immunomodulatory agents and their impact on beta-cell survival.
Main Results:
- Several agents demonstrate potential benefits when administered shortly after type 1 diabetes diagnosis (tertiary prevention).
- No interventions have proven effective in preventing the onset of autoimmunity (primary prevention).
- Significant progress has been made in predicting risk and understanding disease mechanisms.
Conclusions:
- Tertiary prevention strategies show promise for preserving residual beta cells post-diagnosis.
- Further research is needed for effective primary and secondary prevention of type 1 diabetes.
- International collaborations are accelerating knowledge and therapeutic development in this field.
Related Concept Videos
Type I Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
